OncoZenge

Bolag

OncoZenge

OncoZenge är ett svenskt läkemedelsbolag som utvecklar behandlingar för smärtlindring hos patienter som lider av oral smärta orsakad av strålbehandling och kemoterapi mot cancer. Bolagets produktkandidat är efter genomförda fas 2-studier under vidare utveckling till grund för ansökan om regulatoriska marknadsgodkännanden och kommersialisering. OncoZenge har sitt huvudkontor i Bromma.

Senaste publicering

I databasen

46 publicerade PM

Webbplats

Besök bolagets sida

Senaste nyheter och pressmeddelanden

12 visade
ONCOZ

OncoZenge Files New Patent Application to Expand BupiZenge™ IP Protection into Dental and Oral Medical Use

OncoZenge AB (publ) (“OncoZenge” or “the Company”) today announces the filing of a new medical use patent application with the Swedish Intellectual Property Office (PRV), aimed at broadening intellectual property protection for BupiZengeTM into dental and oral medical use. The filing marks a strategic step in safeguarding the potential of BupiZengeTM beyond its lead indication in oral mucositis and into the wider oral pain market.

ONCOZ

OncoZenge AB advances global patent strategy for BupiZenge™ with filings in 17 markets

OncoZenge AB (publ) ("OncoZenge" or “the Company") today announces that it has entered the national and regional phase of its Patent Cooperation Treaty (PCT) application for BupiZengeTM in 17 jurisdictions. The filings were completed within the applicable 30-month PCT deadline and mark the next step in building out global patent protection for BupiZengeTM in support of the Company's commercialization strategy.

ONCOZ

Fourth tranche payment deadline expires without full payment from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd

Following the expiry of the payment deadline, OncoZenge AB (publ) ("OncoZenge" or the "Company") provides the following update on the status of the fourth tranche. The extended payment deadline for the remaining subscription proceeds under the fourth and final tranche of the directed share issue to Sichuan Yangtian Bio-Pharmaceutical Co., Ltd (the “Investor”), pursuant to the investment agreement dated 27 January 2025 between the parties (the “Investment Agreement”), expired today, 28 August 2026, without full payment having been received. In light of previous communication and the uncertainty surrounding the fourth tranche, including the Investor’s letter to the Board dated 27 August 2026 that payment would be withheld, and having regard to the best interests of the Company and its shareholders, the Board of Directors (the “Board”) has not granted any further extension of the payment deadline.

ONCOZ

Investor withholds remaining payment for fourth tranche resulting in short-term liquidity shortfall

OncoZenge AB (publ) ("OncoZenge" or the "Company") has received a letter from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd (the "Investor") with information that the Investor will withhold payment of the remaining subscription proceeds of approximately SEK 10.1 million under the fourth and final tranche of the directed share issue resolved by the Board of Directors and announced on 5 June 2026 (the "Directed Share Issue"), pursuant to the investment agreement dated 27 January 2025 between the parties (the "Investment Agreement"). The payment deadline for the fourth tranche had most recently been extended to 28 August 2026. The Investor has now informed the Company that it is actively withholding payment, which means that the delay can no longer be considered administrative. As a consequence, the Company assesses that payment will not be made by the deadline, and that the Company will face a short-term liquidity shortfall until the Company's ongoing rights issue of approximately SEK 33.3 million, announced on 25 August 2026 (the "Rights Issue"), has been completed.